logo-loader

Creo Medical under the eye of Proactive research analyst Daniel Appiah

Last updated: 12:07 04 Nov 2022 EDT, First published: 08:07 04 Nov 2022 EDT

Creo Medical Group PLC (AIM:CREO) is discussed by Proactive research analyst Daniel Appiah who talks Thomas Warner through his latest report.

Two licensing revenue deals this year will see Creo’s technology used in robotics-assisted laparoscopic (keyhole) surgery to enhance the effectiveness of procedures.

Creo's technology allows minimally invasive endoscopic technology and licensing can be a very important revenue stream in future, Appiah adds. #proactiveinvestors #creomedical

Click here to read the report

Creo Medical Group reveals good growth prospects at Capital Markets Day -...

Creo Medical Group PLC (AIM:CREO), an innovative UK-based medical technology company, recently showcased significant advancements during their Capital Markets Day, as highlighted by Proactive Research Analyst John Savin in his latest research note. The primary focus was on Creo's new version...

on 11/27/2023
OSZAR »